A recent Globe and Mail article discussed the eyelash treatment Latisse.
Available already in the USA, India, Argentina and Chile, Latisse recently obtained approval from Health Canada and is available by prescription for the treatment of eyelash hypotrichosis, or an inadequate amount of lashes. Certainly sounds like they’re making this one sound like a disease (surely it isn’t). Despite this, Latisse is expected to be a huge seller in Canada (as it is in the USA). In fact, global sales are expected to exceed $500 million.
Latisse was developed when the glaucoma medication Lumigan was found to have an unexpected side effect that resulted in longer, darker and fuller eyelashes. Allergan, the manufacturer of Lumigan went on to develop Latisse, a topical product that is applied to the base of lashes with a small brush.
If you want to embrace Latisse, you should know that it does come with some risks including itchy, red eyes and even darkening of the skin around the eyes. In some rare cases, it’s been found to permanently darken an individual’s eye colour. And because it is relatively new, there has been very little experience with the consequences of long term use.
Is Latisse worth the risk?
